AletheiaHQ
Sign In
DIR-D8-2D3-9R9V/LVL 4·Multi-disciplinary TeamScoped operation requiring two or more distinct Vectors (disciplines). Cannot be executed solo. Examples: developer + lawyer targeting a new EU regulation compliance gap; logistics operator + finance operator arbitraging a carbon-tax supply disruption./80% confidence
Return to Directory

Monetize NIH Gene Therapy Database via Pharma Intelligence Subscription

Organization
NIH public grant database (RePORTER) containing detailed technical specifications of funded projects
Sector
Pharmaceutical business development teams desperate for early-stage gene therapy deal flow
Location
Location unspecified

Source Reference

https://reporter.nih.gov/project-details/1R41EY039138-01

// Venture Capital// Biotech// Database Management// Data Scraping// Machine Learning & Modeling// IP// Health Policy & Regulation// Data Engineering & Pipelines

Executive Context

NIH awarded $311,049 Phase I STTR funding to OUTFLOWGEN LLC for a first-in-class CRISPR glaucoma therapy, creating a predictable commercial gap where scientific validation exists but commercialization infrastructure is absent. The structural asymmetry is between NIH's ability to fund early science and small biotechs' inability to navigate the regulatory and capital requirements for clinical development.

Catalyst / Timing

NIH RePORTER contains granular technical data on thousands of funded gene therapy projects (CRISPR guides, delivery methods, disease targets) but this data is unstructured and not organized for commercial intelligence. Pharma BD teams spend millions on consultants to find early-stage assets, but lack systematic access to this publicly funded pipeline.

Projected Yield

$750k ARR from 10 pharma clients at $75k/year each

Structural Friction

• Vulnerability: NIH RePORTER contains granular technical data on thousands of funded gene therapy projects (CRISPR guides, delivery methods, disease targets) but this data is unstructured and not organized for commercial intelligence. Pharma BD teams spend millions on consultants to find early-stage assets, but lack systematic access to this publicly funded pipeline. • Capital yield: $750k ARR from 10 pharma clients at $75k/year each • Resource capture: Exclusive relationships with pharma BD teams as their primary early-stage sourcing tool • Influence capture: Authority position as the definitive source for NIH-funded gene therapy intelligence • Sovereignty yield: Proprietary database of NIH gene therapy pipeline with predictive scoring algorithm • Required vectors: Vector: Data Engineering & API Integration, Vector: Biotech Market Intelligence, Vector: SaaS Product Development

Required Capabilities

  • Vector: Data Engineering & API Integration

    Primary executor: Phase 1: Database Architecture & Initial Scrape: Build Python scraper to extract all R41/R42 (STTR) and R43/R44 (SBIR) g

  • Vector: Biotech Market Intelligence

    Supporting vector for: Monetize NIH Gene Therapy Database via Pharma Intelligence Subscription

  • Vector: SaaS Product Development

    Supporting vector for: Monetize NIH Gene Therapy Database via Pharma Intelligence Subscription

Execution Protocol

Execution Protocol Locked

A one-time payment of $649 unlocks the exact wedge, required assets, and step-by-step execution parameters yours forever, no subscription.

This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.